Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Share this content:
Higher tumor-infiltrating lymphocyte values in tumor stroma are associated with longer overall survival.
Higher tumor-infiltrating lymphocyte values in tumor stroma are associated with longer overall survival.

Among patients with advanced HER2+ breast cancer, higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS), according to findings from a secondary analysis of the CLEOPATRA (ClinicalTrials.gov Identifier: NCT00567190) trial presented at the 2016 San Antonio Breast Cancer Symposium and published in The Lancet Oncology.1,2

“The positive influence of pre-existing antitumor immunity persists in the advanced setting,” reported lead study author Stephen J. Luen, MBChB, of the Sherene L Peter MacCallum Cancer Centre, University of Melbourne, Australia. “Each 10% increase in stromal TILs was associated with an 11% reduction in the risk of death.”

CLEOPATRA participants were administered first-line docetaxel, trastuzumab, and either pertuzumab or placebo. The association between OS and TILs was linear and did not differ between treatment groups. “No predictive effect was observed with regard to pertuzumab treatment,” Dr Luen said.

“Tumor TILs are associated with improved pathological complete response rates as well as survival” in other settings, Dr Luen noted. But their association with outcomes in the setting of advanced HER2+ breast cancer has not been previously examined.

The new analysis was based on 678 CLEOPATRA participants for whom TIL data were evaluable; 23% of samples were freshly obtained (within 45 days of randomization) and 519 were archival.

RELATED: Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

The 3-year OS among patients who received pertuzumab and had stromal TILs exceeding 20% was 78%. There was a statistically-non-significant trend between higher TILs and improved progression-free survival.

Strategies to augment immunity in advanced breast cancer might further improve survival rates, Dr Luen said.

Reference

  1. Luen SJ, Salgado R, Fox S, et al. Prognostic associations of tumor-infiltrating lymphocytes (TILs) in advanced HER2-positive breast cancer treated with pertuzumab and trastuzumab: a secondary analysis of the CLEOPATRA study. Paper presented at: 39th San Antonio Breast Cancer Symposium; Dec 2016; San Antonio, TX.
  2. Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab and trastuzumab: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2016 Dec 7. doi: 10.1016/S1470-2045(16)30631-3 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs